Hepcidin Research: What 6,522 Studies Show (2026) | RetatrutideCompare

Hepcidin — 6,522 studies indexed on PubMed. Master regulator of iron homeostasis. Binds and triggers ferroportin internalization, blocking iron efflux from enterocytes and macrophages. Half-life: ~6 hours. FDA status: Native not approved; analogs (Rusfertide) in trials.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Hepcidin?

There are approximately 6,522 studies indexed on PubMed that mention Hepcidin (LEAP-1), based on a search last updated 2026-06-18.

Is Hepcidin FDA-approved?

FDA status: Native not approved; analogs (Rusfertide) in trials.

How does Hepcidin work?

Master regulator of iron homeostasis. Binds and triggers ferroportin internalization, blocking iron efflux from enterocytes and macrophages.

Reference facts

Also known as: LEAP-1
Category: Neuropeptide & Other
Mechanism of action: Master regulator of iron homeostasis. Binds and triggers ferroportin internalization, blocking iron efflux from enterocytes and macrophages.
Targets: Ferroportin
Indications under research or approved: Diagnostic biomarker; research in iron overload (hereditary hemochromatosis) and anemia of chronic disease
Regulatory status (reference entry): Native not approved; analogs (Rusfertide) in trials
Half-life: ~6 hours
Sequence: DTHFPICIFCCGCCHRSKCGMCCKT
Sequence notes: 25-residue hepatic peptide with four disulfide bonds.
Molecular weight (Da): 2789
PDB accession: 1M4F
First reported: 2000

Primary References

Park et al., JBC 2001 (Hepcidin)

Explore research articles about Hepcidin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.